where's the news on this??, page-62

Looks like the analysts are also picking it up...in * referring to analyst Scott Power at Morgans

”Elsewhere, another health stock that Power has his eyes on is Actinogen (ASX:ACW).Actinogen is involved in the early stage treatment of cognitive impairment diseases, primarly in early stage dementia such as Alzheimer’s disease.“It’s pre-revenue and in the drug development phase. But a new CEO recently joined that company, and he’s got a very good reputation with repositioning companies,” Power argued.In March, the company appointed Dr Steven Gourlay as its new CEO. Dr Gourlay has more than 30 years’ experience in the development of novel therapeutics, and was the chief medical officer at US-based Principia Biopharma.”